Author name: Leonardo Arias

Un pulpo puede curvar con destreza una parte de un tentáculo alrededor de un obstáculo, mientras otra se introduce en una pequeña grieta para agarrar un objeto. Replicar ese control local tan sofisticado en un robot blando requiere múltiples actuadores (componentes que tr …

Las agresiones sexuales facilitadas por drogas, como la escopolamina (popularmente conocida como burundanga), constituyen un grave problema de salud pública y forense. Esta sustancia es especialmente peligrosa debido a sus potentes efectos amnésicos, sedantes y alucinógenos, a l …

Hanlon, who has worked in a variety of leadership roles at Highmark during nearly three decades with the company, will be the organization’s first-ever female CEO.

The Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness.

Patients can view their pulmonary artery pressure readings on their phone with the CardioMEMS updates, giving them a more active role in their care.

ArriVent BioPharma’s Phase 3 lung cancer trial was clouded by stronger-than-expected data for patients receiving chemotherapy, prompting analysts to pivot focus to a late-stage test of the tyrosine kinase inhibitor in a different type of lung cancer and to the biotech’s antibody-drug conjugate pipeline.

Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including Novartis, AbbVie and Pfizer.

Forbion participated in the November 2025 series B round of Gate Bioscience, which earlier this week inked an up to $870 million deal extension with Eli Lilly.

The investment will equip Bayer to make oncology, cardiovascular and renal care ingredients and drugs.

New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last